Positive News SentimentPositive News Cassava Sciences Stock Price, News & Analysis (NASDAQ:SAVA) $20.80 -0.03 (-0.14%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$20.67▼$21.3050-Day Range$12.64▼$24.2452-Week Range$12.32▼$45.43Volume591,297 shsAverage Volume838,388 shsMarket Capitalization$877.14 millionP/E RatioN/ADividend YieldN/APrice Target$76.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Cassava Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside265.4% Upside$76.00 Price TargetShort InterestBearish36.80% of Float Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.22) to $1.18 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector434th out of 952 stocksPharmaceutical Preparations Industry200th out of 448 stocks 3.5 Analyst's Opinion Consensus RatingCassava Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $76.00, Cassava Sciences has a forecasted upside of 265.4% from its current price of $20.80.Amount of Analyst CoverageCassava Sciences has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted36.80% of the float of Cassava Sciences has been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in Cassava Sciences has recently decreased by 8.94%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCassava Sciences has received a 74.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for Alzheimer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Cassava Sciences is -0.82. Previous Next 3.3 News and Social Media Coverage News SentimentCassava Sciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cassava Sciences this week, compared to 3 articles on an average week.Search Interest51 people have searched for SAVA on MarketBeat in the last 30 days. This is an increase of 28% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -42% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of Cassava Sciences is held by insiders.Percentage Held by InstitutionsOnly 27.19% of the stock of Cassava Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cassava Sciences are expected to grow in the coming year, from ($2.22) to $1.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -9.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -9.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 5.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cassava Sciences Stock (NASDAQ:SAVA)Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.Read More SAVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAVA Stock News HeadlinesNovember 23, 2023 | morningstar.comCassava Sciences Inc SAVANovember 22, 2023 | finance.yahoo.com7 High-Risk, High-Reward Stocks for the Extreme ContrarianDecember 2, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 9, 2023 | finance.yahoo.comCassava Sciences, Inc. (NASDAQ:SAVA): Is Breakeven Near?November 8, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Cassava Sciences (SAVA), CymaBay Therapeutics (CBAY)November 8, 2023 | marketwatch.comIonQ Announces Third Quarter 2023 Financial ResultsNovember 8, 2023 | markets.businessinsider.comGinkgo Bioworks Reports Third Quarter 2023 Financial ResultsNovember 7, 2023 | msn.comCassava Sciences Q3 costs rise amid late-stage Alzheimer’s programDecember 2, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 7, 2023 | msn.comCassava Sciences GAAP EPS of -$0.61 beats by $0.29November 7, 2023 | finance.yahoo.comCassava Sciences Reports Third Quarter 2023 Financial and Operating ResultsNovember 7, 2023 | finance.yahoo.comCassava Sciences Inc (SAVA) Reports Q3 2023 Financial ResultsNovember 6, 2023 | msn.comCassava Sciences fully enrolls Phase 3 program for Alzheimer’s candidateNovember 6, 2023 | finance.yahoo.comCassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s DiseaseNovember 3, 2023 | msn.comCassava Sciences' Simufilam Does Not Appear To Be Effective Against Alzheimer's DiseaseOctober 31, 2023 | finance.yahoo.com1 Big Red Flag to Fear When a Stock Is DownOctober 30, 2023 | msn.comCassava Sciences: My Bullish Take On Biomarkers And CTAD DataOctober 28, 2023 | nytimes.comCUNY Halts Investigation of Alzheimer’s ResearcherOctober 25, 2023 | markets.businessinsider.comWhy Cassava Sciences Stock Surged TodayOctober 25, 2023 | msn.comCassava Sciences gains after safety data for Alzheimer’s candidateOctober 25, 2023 | finance.yahoo.comMRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)October 17, 2023 | benzinga.comInvestigation of Cassava Sciences, Inc. (SAVA) Announced by Holzer & Holzer, LLCOctober 16, 2023 | dailymail.co.uk$500m Alzheimer's drug scandal: NY scientist behind NIH-funded therapy busted for allegedly manipulating data in 20 research papers - now there are calls for trials to be cut offOctober 14, 2023 | nytimes.comScientists Investigating Alzheimer’s Drug Faulted in Leaked ReportOctober 13, 2023 | msn.comCassava stock falls 15% in wake of negative report on CUNY researcherOctober 13, 2023 | bizjournals.comLeaked report brings new scrutiny on Alzheimer’s drug developed by Austin companyOctober 13, 2023 | wsj.comCassava Stock Sinks After University Investigation Into ScientistSee More Headlines Receive SAVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/02/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SAVA CUSIPN/A CIK1069530 Webwww.cassavasciences.com Phone(512) 501-2444Fax512-501-0414Employees26Year FoundedN/APrice Target and Rating Average Stock Price Target$76.00 High Stock Price Target$124.00 Low Stock Price Target$28.00 Potential Upside/Downside+265.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,250,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.83% Return on Assets-46.40% Debt Debt-to-Equity RatioN/A Current Ratio8.62 Quick Ratio8.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.68 per share Price / Book5.65Miscellaneous Outstanding Shares42,170,000Free Float38,378,000Market Cap$877.14 million OptionableNot Optionable Beta-0.03 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Remi Barbier (Age 63)Founder, Chairman, President & CEO Comp: $1.11MMr. Eric J. Schoen (Age 55)Chief Financial Officer Comp: $426.61kMr. R. Christopher Cook (Age 59)Senior VP, Company Secretary & General Counsel Comp: $457.64kDr. James W. Kupiec M.D. (Age 70)Chief Medical Officer Comp: $400kDr. George ThorntonSenior Vice President of TechnologyMr. Michael ZamlootSenior Vice President of Technical OperationsDr. Michael Marsman Pharm.D.Senior Vice President of Regulatory AffairsDr. Lindsay H. Burns Ph.D.Senior Vice President of NeuroscienceMore ExecutivesKey CompetitorsInnovivaNASDAQ:INVAAlpine Immune SciencesNASDAQ:ALPNAmylyx PharmaceuticalsNASDAQ:AMLXKeros TherapeuticsNASDAQ:KROSPliant TherapeuticsNASDAQ:PLRXView All CompetitorsInsiders & InstitutionsDeutsche Bank AGBought 1,271 shares on 11/24/2023Ownership: 0.051%Walleye Trading LLCBought 1,900 shares on 11/21/2023Ownership: 0.000%Walleye Capital LLCSold 5,600 shares on 11/21/2023Ownership: 0.000%Wolverine Trading LLCBought 13,300 shares on 11/16/2023Ownership: 0.000%GTS Securities LLCBought 55,600 shares on 11/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SAVA Stock Analysis - Frequently Asked Questions Should I buy or sell Cassava Sciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SAVA shares. View SAVA analyst ratings or view top-rated stocks. What is Cassava Sciences' stock price target for 2024? 1 Wall Street research analysts have issued 12 month target prices for Cassava Sciences' stock. Their SAVA share price targets range from $28.00 to $124.00. On average, they expect the company's share price to reach $76.00 in the next year. This suggests a possible upside of 265.4% from the stock's current price. View analysts price targets for SAVA or view top-rated stocks among Wall Street analysts. How have SAVA shares performed in 2023? Cassava Sciences' stock was trading at $29.54 at the beginning of 2023. Since then, SAVA stock has decreased by 29.6% and is now trading at $20.80. View the best growth stocks for 2023 here. When is Cassava Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our SAVA earnings forecast. How were Cassava Sciences' earnings last quarter? Cassava Sciences, Inc. (NASDAQ:SAVA) released its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.61) EPS for the quarter, topping analysts' consensus estimates of ($0.90) by $0.29. What ETFs hold Cassava Sciences' stock? ETFs with the largest weight of Cassava Sciences (NASDAQ:SAVA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL).iShares U.S. Pharmaceuticals ETF (IHE). When did Cassava Sciences' stock split? Cassava Sciences's stock reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA). Who are Cassava Sciences' major shareholders? Cassava Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Gallacher Capital Management LLC (1.37%), Northern Trust Corp (0.89%), Charles Schwab Investment Management Inc. (0.73%), SG Americas Securities LLC (0.66%), Barclays PLC (0.00%) and Bank of New York Mellon Corp (0.32%). Insiders that own company stock include Eric Schoen, James William Kupiec, Richard Barry and Sanford Robertson. View institutional ownership trends. How do I buy shares of Cassava Sciences? Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:SAVA) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.